Last reviewed · How we verify
Eryped (Erythromycin ethyl succinate)
At a glance
| Generic name | Erythromycin ethyl succinate |
|---|---|
| Sponsor | Arbor Pharms Llc |
| Drug class | Macrolide |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1965 |
Approved indications
- Bacterial pneumonia
- Bacterial septicemia
- Burn Wound Infections
- Cholangitis
- Hepatic coma
- Infection of bone
- Infection of skin AND/OR subcutaneous tissue
- Infectious disease of abdomen
- Infectious disorder of joint
- Meningitis
- Preoperative Bowel Preparation
- Urinary tract infectious disease
Common side effects
Key clinical trials
- Improving Care Through Azithromycin Research for Infants in Africa (PHASE3)
- A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction (PHASE3)
- Azithromycin Reduction to Reach Elimination of Trachoma (PHASE4)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- A Study of Standard Drugs for Mycobacterium Avium Complex (PHASE2)
- An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM (PHASE3)
- Antibiotic Treatment of Recurrent Episodes of Asthma in Children (PHASE2)
- Azithromycin Reduction to Reach Elimination of Trachoma B (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Eryped CI brief — competitive landscape report
- Eryped updates RSS · CI watch RSS
- Arbor Pharms Llc portfolio CI